Participated · Series C · Jun 2026

HyperLight develops high-performance integrated photonics based on thin-film lithium niobate (TFLN), commercialized as its TFLN Chiplet™ Platform. The platform targets a range of optical interconnect applications including data center pluggables, coherent datacom and telecom modules, and co-packaged optics, and offers products supporting 200G-per-lane operation with 400G-per-lane solutions now sampling. The company emphasizes ultra-high modulation bandwidth, CMOS-level drive voltage, and ultra-low optical loss to reduce power consumption at higher lane speeds. HyperLight has established a strategic manufacturing partnership with UMC and Wavetek for high-volume foundry production on both 6-inch and 8-inch wafers. With the $80 million Series C, the company plans to expand manufacturing capacity, accelerate customer qualification, scale its platform, and deepen partnerships across foundry, semiconductor, networking, and systems integration domains.

Participated · Series B · Aug 2025

Multibeam builds production-grade multi-column electron-beam lithography (EBL) tools that offer a full-wafer field of view, exceptional depth of focus, maskless writing, and the ability to create unique patterns. The company shipped its first EBL production system last year and has seen increased interest from semiconductor manufacturers. Its platform is positioned to enable new chip designs for quantum computing, photonics, advanced packaging and other emerging applications. Multibeam plans to accelerate development of a next-generation EBL platform for 300mm wafers and panel-level maskless lithography. The company says these capabilities can support denser interconnects, lower energy consumption and higher performance for AI and related technologies. Strong partnerships with industry investors are expected to aid its next phase of growth.

Participated · Equity · Jan 2025

UVeye is an AI-driven vehicle inspection technology company that provides automated, data-driven diagnostics often described as an "MRI for vehicles". Its product suite includes underbody scanners, tire analyzers, and 360-degree exterior detection systems. Those systems have been installed at hundreds of dealerships, fleet sites, and auction lots globally. Clients include Amazon and General Motors. Led by CEO Amir Hever and based in Teaneck, NJ, the company raised $191M in the latest funding round, bringing total capital raised to $380.5M. UVeye plans to use the funds to expand globally, increase large-scale manufacturing capacity, and strengthen strategic partnerships. UVeye builds automated vehicle-inspection systems that use computer vision and machine learning to quickly and accurately inspect vehicles. The company produces three inspection systems: an underbody scanner, a tire system, and a 360-degree exterior system that can scan moving vehicles in seconds. Since its founding in 2016, UVeye has secured commercial agreements with OEMs and dealers including General Motors, Volvo Cars USA and CarMax and supports dealerships, auctions, insurance companies and commercial fleets. The company employs about 200 people and is based in New Jersey and Tel Aviv, with additional offices in Japan and Germany. UVeye plans to start production of its inspection systems in North America and accelerate sales growth to reach thousands of dealerships, used-car auctions and fleets within the next three years. Management sees longer-term opportunities serving EVs, autonomous and robotaxi fleets for safety and predictive maintenance by combining vehicle sensors with UVeye's capabilities. Financially, the company has raised roughly $200 million since 2016 and its valuation is about $800 million after the latest round. UVeye develops high-speed automated vehicle-inspection systems that combine proprietary algorithms, cloud architecture, artificial intelligence, machine learning and sensor fusion. Its drive-through scanners detect external and mechanical flaws, anomalies, modifications and foreign objects from under and from any side of a vehicle, completing scans within seconds and usable across a vehicle’s lifecycle. The technology was originally developed for the security industry to detect weapons and contraband and is now applied in the automotive industry to find quality issues such as oil leaks, paint scratches, tire damage, brake-line damage and exhaust-system problems. Founded in 2016 and based in Tel Aviv, Israel, UVeye operates facilities in North America, Europe and the Asia Pacific region, with offices in Israel, Japan, Germany and the U.S. The company has 100 employees. UVeye raised $60m in Series C funding and intends to use the proceeds for global expansion. UVeye develops automated vehicle-inspection systems that combine proprietary algorithms, cloud architecture, artificial intelligence, machine learning and sensor fusion to standardize and speed previously manual inspections. Its platforms serve both homeland security and automotive customers across the vehicle lifecycle, including supplier and OEM assembly lines, new-car showrooms, dealership service departments and used-vehicle auction sites. The company has installed systems at assembly plants, auction sites and dealerships around the world and has offices in Tel Aviv, Cleveland and New York, as well as locations in Japan and Germany. UVeye is led by CEO and co-founder Amir Hever and employs more than 100 people. The company says it will use the new funds to accelerate its global expansion plans and to enable Hyundai to deploy UVeye’s products across its operations worldwide. Since it was founded four years ago, UVeye has raised more than $40m from carmakers and other strategic investors including W. R. Berkley Corporation. UVeye develops vertically integrated drive-through scanning systems (hardware and software) that capture exterior, tire and undercarriage images and use computer vision and AI to detect anomalies. Its fully automated platform can read moving cars (up to ~20 mph) and detect cosmetic anomalies as small as 2 millimeters. Customers and use cases include OEMs, rental and used-car companies, insurers, security services, governments and ride-hailing fleets for inspections, claims and lifecycle management. The company is exploring deeper integration with vehicle diagnostics and potential expansion into interior/cargo scanning and logistics/security verticals. UVeye emphasizes full automation to replace manual inspections and continues to optimize its system and scale deployment to meet demand. Financially, the company has raised a new $31M round, bringing total capital raised to about $35M.

Participated · Series B · Jul 2024

DreamBig Semiconductor develops a chiplet platform that enables modular semiconductor solutions centered on its Chiplet Hub™ and Platform Chiplets. The company offers high-performance accelerator platforms and networking chiplets targeting LLMs, generative AI, data centers, edge computing, and automotive applications. Key capabilities include universal architecture support for CPU, AI, accelerator, I/O, networking, and memory chiplets within a unified platform and a Memory-First Architecture providing direct access to 3D stacked HBM, DDR, CXL, and SSD memory tiers. Additional technical features highlighted are fully associative hardware acceleration for cache/memory management (FLC Technology Group), DMA hardware for efficient transfers, a virtual PCIe/CXL switch, Ethernet/UEC RDMA hardware, and multi‑gigabit, low‑power CAM for 800Gbps match/action processing. The company intends to use the recently raised funds to accelerate development and commercialization of products built on its Chiplet Hub and Platform Chiplets. Led by CEO Sohail Syed, DreamBig positions itself to scale processor, accelerator, and networking chiplets across heterogeneous memory and compute domains.

Participated · Series B · Mar 2024

Hengyu Biotech offers a comprehensive, high-standard international service platform for biosafety testing aimed at global innovative drug companies. Its services include virus clearance process validation, cell bank characterization, replication-competent virus detection (RCL, RCR, rcAAV, RCA), batch release testing, CGT bioanalysis, and process residuals detection. The company’s offerings cover biologics from early development through regulatory submission and market launch. Hengyu emphasizes meeting submission requirements across China, the U.S., and Europe. Recently it completed a near ¥200 million B round, strengthening its financial position for growth. The company plans to use the proceeds to enhance its internationally compliant quality systems, expand its product line, and accelerate overseas business development.